Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q1 2026

CytoDyn Q1 2026 Results: Net Loss of $19.9M, Loss Widens

CytoDyn reported a net loss of $19.9 million for the quarter ended August 31, 2026, significantly higher than the $5.5 million loss in the prior year due to a $12.3 million loss on note extinguishment. The company continues to express substantial doubt about its ability to continue as a going concern, with an accumulated deficit of $950.4 million.

Q1 2026 at a glance · $ million
MetricQ1 2026Q1 2025
Profit before tax-19.9-5.5
Net income-19.9-5.5
EPS (diluted, $ a share)$-0.01$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: CYDY. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

CytoDyn Inc.: key numbers

Share price
$0.2502Close, Nov 16
Market cap
$368M
Shares outstanding
1.47BLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from CytoDyn Inc.

All →
4:51 PM ET 8-K
Leadership Change

CytoDyn Leadership Change

CytoDyn appointed Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026, succeeding Dr. Jacob Lalezari. Dr. Lalezari resigned from the CEO role but will remain with the company as Head of Research and Translational Sciences. Mr. Hoffman, who previously served as the company's CFO, will also continue to serve as the principal accounting officer.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.